Accent Microcell Ltd
ACCENTMICAccent Microcell Ltd's price has outrun its earnings. +176.0% in a year against EPS +32.7% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only 51% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (63 weeks in) while the P/E sits at the 98th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +52.9% year on year, and 51% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Accent Microcell Ltd trades at ₹675, in a confirmed uptrend and 63 weeks into that stage. That is +44.1% against its own 200-day average. It sits at 88% of a 52-week range of ₹308 to ₹726. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 50 straight weeks.
Today the stock is in a confirmed uptrend — week 63 of stage 2, confirmed. At ₹675 it trades +44.1% versus its 200-day average and sits at 88% of its 52-week range (₹308–₹726).
Against the market, two honest reads. Cumulative: over the last 2.8 years the stock moved +126% while the NIFTY 500 moved +20% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 50 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Accent Microcell Ltd's story is not scored yet against the markers our research file set on 17 May 2026. Where it sits in its own cycle: FIRST_TIME_EXPANSION_5Y. Our fortnightly research layers last read it on 19 July 2026.
Our read, 17 May 2026. A niche MCC excipient compounder with a credible premium-product pivot — undercut by a management credibility deficit that makes the capacity ramp ununderwritable at current PE.
From the numbers. PE expanded 74% from Mar 2025 trough of 16.9x to current 29.4x — the cycle data labels this FIRST_TIME_EXPANSION_5Y as PE had not previously expanded beyond 32.5x in the 5Y history. At 73rd percentile (median 20.4x)…
From the price. Price stage 2, week 63 — above its 200-day line, relative strength rising.
From the research. A niche MCC excipient compounder with a credible premium-product pivot — undercut by a management credibility deficit that makes the capacity ramp ununderwritable at current PE.
🚨 Where they disagree. PE expanded 74% from Mar 2025 trough of 16.9x to current 29.4x — the cycle data labels this FIRST_TIME_EXPANSION_5Y as PE had not previously expanded beyond 32.5x in the 5Y history. At 73rd percentile (median 20.4x), stock is NEAR_PEAK but EPS trajectory is upward (Q4 FY26 EPS Rs 10.75 vs Rs 6.86-7.53 prior quarters). DII accumulation is a consistent positive signal. Low data reliability flagged (data_sufficiency: MODERATE) — Bronze tier conviction appropriate.
What is proven. A niche MCC excipient compounder with a credible premium-product pivot — undercut by a management credibility deficit that makes the capacity ramp ununderwritable at current PE.
What is not proven yet. Phase 1 already 8-9 months late; GPCB approval actively denied in May 2025 but was primary delay cause; June 25, 2026 target is contingent on regulatory receipt — another slip would be the 4th documented failure.
🚨 Layer 1 read, 19 July 2026 — DROP. Real premium-product pivot, but the multiple re-rated ahead of a ramp management has missed three times. The PE has already climbed to the 73rd percentile (29.4x vs a 20.4x median, up 47% over eight quarters) while per-share earnings are only weakly recovering and the headline growth is inflated by a low FY22 base. The re-rating rests on a premium-capacity ramp (Unit 3 Phase 1) that is now 8-9 months late for the third time and gated on a GPCB approval management first denied was pending and then blamed for the delay — so the multiple is running ahead of a delivery record that does not yet earn it.
What would change Layer 1’s mind. Unit 3 Phase 1 commercialization confirmed with premium mix reaching 15%+ (Milestones M1/M2) would validate the ramp and re-earn the multiple, lifting this toward P1; conversely silence past the July-15 2026 'absolute latest' management deadline would confirm the credibility break and push it toward DROP.
The test written in advance. Management credibility — Unit 3 delayed again (3rd miss) — Management credibility — Unit 3 delayed again (3rd miss) June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag by the next result.
The test written in advance. PE at 73rd percentile on normalised growth of 14-16% — PE at 73rd percentile on normalised growth of 14-16% by the next result.
The test written in advance. Wood pulp and alpha cellulose input cost volatility — Wood pulp and alpha cellulose input cost volatility Quarterly OPM below 15% = input cost headwind materialising by the next result.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Premium Product Mix Shift (CCS + silicated… | HIGH | — | Premium products at 13% of FY26 revenue at 3x average realization (Rs 600-900/kg vs Rs 260/kg blended) — Unit 3 Phase 1 adds… | June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag |
| Geographical Expansion (60% export, 45+… | MEDIUM_HIGH | — | Export share rose to 60% (Rs 210 Cr) in FY26 from ~53% prior year — Dahej SEZ technology commands premium pricing in US/EU… | June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag |
| Unit 3 Phase 1 Capacity Ramp (2,400 MT, Rs… | HIGH | — | 2,400 MT fungible capacity (CCS/CMC/silicated MCC) with Rs 150 Cr peak revenue potential at Rs 600-700/kg — contingent on… | June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag |
| Trading Revenue Exit + Manufacturing… | MEDIUM | — | Rs 90 Cr (26% revenue) trading at 2-6% margin planned for substantial reduction post Phase 2; exit improves blended PAT margin… | June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag |
| DII Accumulation + Growing Institutional… | LOW | — | DII holding grew from 1.62% (Mar 2024) to 3.57% (Dec 2025) — quiet institutional accumulation at sub-1,100 Cr MCap. | June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag |
Lever 9 · Buyback — BUILDING. Premium products at 13% of FY26 revenue at 3x average realization (Rs 600-900/kg vs Rs 260/kg blended) — Unit 3 Phase 1 adds 2,400 MT dedicated premium capacity from June 2026. What proves it keeps working: Premium Product Mix Shift (CCS + silicated MCC + MCC Spheres). It stops working if June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag.
Lever 10 · New geographies — BUILDING. Export share rose to 60% (Rs 210 Cr) in FY26 from ~53% prior year — Dahej SEZ technology commands premium pricing in US/EU regulated markets; no China input exposure. What proves it keeps working: Geographical Expansion (60% export, 45+ countries, regulated market penetration). It stops working if June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag.
Lever 6 · Order-book wins — BUILDING. 2,400 MT fungible capacity (CCS/CMC/silicated MCC) with Rs 150 Cr peak revenue potential at Rs 600-700/kg — contingent on GPCB/CTO/CCA approvals by June 25, 2026. What proves it keeps working: Unit 3 Phase 1 Capacity Ramp (2,400 MT, Rs 150 Cr peak revenue). It stops working if June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag.
Lever 8 · Demerger or value unlock — BUILDING. Rs 90 Cr (26% revenue) trading at 2-6% margin planned for substantial reduction post Phase 2; exit improves blended PAT margin by 200-300 bps mechanically. What proves it keeps working: Trading Revenue Exit + Manufacturing Margin Expansion. It stops working if June 25, 2026 Phase 1 commercialization announcement — silence past July 15 = red flag.
Sources: our stock research file (17 May 2026) · quarterly results through Mar 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Accent Microcell Ltd reported ₹210 Cr of revenue in the Mar 26 quarter, +51.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 7 years it has compounded at 17.3% a year. The last full year, FY26, came in at ₹349 Cr. The last four reported quarters add to ₹614 Cr.
Why this happened. Regulated market export is the structural revenue quality upgrade. Dahej SEZ spray-dryer produces pharma-grade MCC accepted in regulated markets. Export revenue is higher-margin than domestic (Rs 170-190/kg domestic vs premium-priced Dahej exports). The zero China supply chain exposure (USA, Sweden, Canada, Indonesia sourcing) is a genuine competitive moat in current geopolitical context. Phase 2 (MCC export line, March 2027 target) specifically targets established 20+ year customer relationships for high utilization from Year 1.
FY26 revenue came in at ₹349 Cr (+31.7% on the year), capping 7 years at 17.3% compound. The latest quarter (Mar 26) printed ₹210 Cr, +51.1% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +19.8% growth against the decade's 17.3% — the current year is running faster than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Accent Microcell Ltd's operating margin is 16.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.0 percentage points. Across 8 fiscal years the operating margin has ranged 4.9% to 16.0%.
The latest quarter's operating margin is 16.0%, −1.0 pp against the same quarter a year ago. Across 8 fiscal years the operating margin has ranged 4.9%–16.0%, and FY26's 16.0% is the top of that band — a record year.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +0.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Accent Microcell Ltd earned ₹26.0 Cr of net profit in the Mar 26 quarter, +52.9% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹44.0 Cr. The 7-year compound rate is 40.9%. That is 12.4% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Mar 26 profit was ₹26.0 Cr, +52.9% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹44.0 Cr (+33.3%), and the 7-year compound rate is 40.9%.
Why profit moved: revenue contributed +51.1% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +21.5% vs revenue +19.8%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 51% of Accent Microcell Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹19.0 Cr of operating cash against ₹44.0 Cr of profit. After ₹99.0 Cr of capital spending, ₹−80.0 Cr was left as free cash.
FY26: operating cash of ₹19.0 Cr against reported profit of ₹44.0 Cr, leaving free cash of ₹−80.0 Cr after ₹99.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 51% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 51%: the cash cycle stretched 29 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 29 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Accent Microcell Ltd's cash conversion cycle runs 117 days in FY26, up from 88 days in FY21. Capital spending ran ₹137 Cr over the last 3 years. At FY26 sales of ₹349 Cr each day of that cycle holds about ₹1.0 Cr, so roughly ₹112 Cr sits inside the business at any moment.
FY26: debtors at 95 days, inventory at 55 days — roughly 1.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 117 days, looser than FY21's 88.
The full loop: cash goes out to suppliers and production on day 0; stock waits 55 days to sell; customers pay about 95 days after that; and suppliers themselves are paid at 33 days — netting out to the 117-day cycle.
In money terms: at FY26 sales of ₹349 Cr, each day of the cycle holds about ₹1.0 Cr — so the 117-day loop keeps roughly ₹112 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹137 Cr over the last 3 fiscal years against ₹13.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹102 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Accent Microcell Ltd earns a ROCE of 25% in FY26. That is up from a trough of 17% in FY21. Return on invested capital clears the cost of that capital by +3.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.6% net margin on 1.08× asset turns.
FY26 ROCE is 25%, recovered from a FY21 trough of 17% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.6% net margin × 1.08× asset turns × 1.17× balance-sheet leverage ≈ 15.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 15.9% − 12.0% = a +3.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Accent Microcell Ltd carries total debt of ₹1.0 Cr against shareholder equity of ₹275 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.08 in FY24 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1.0 Cr against shareholder equity of ₹275 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.08 (FY24) to 0.00 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 2.1 points of Accent Microcell Ltd over 7 quarters, the biggest move on the register. That takes promoters to 53.0% of the company. Domestic institutions moved +1.9 points over the same window, to 3.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
Why this happened. The core structural thesis. Accent's differentiation from commodity MCC is the pulp-based CCS process (8-year R&D, first commercial India deployment) and spray-dryer Dahej technology. H2 FY26 showed premium products accelerating to 13% of revenue with silicated MCC and MCC Spheres both scaling. Phase 1 (2,400 MT) is fungible across CCS/CMC/silicated MCC — once operational, it unlocks the 16-17% FY27 premium mix target. The realization differential (Rs 600-700/kg for CCS vs Rs 260/kg base) means even modest Phase 1 volumes are highly PAT-accretive. The risk is the Phase 1 delay record.
The register over the last two years — Promoters: −2.1 points over 7 quarters to 53.0%; Domestic institutions: +1.9 points over 7 quarters to 3.5%; Foreign institutions: +0.9 points over 7 quarters to 0.9%.
🚨 Why the register moved: promoters drove it (−2.1 points), absorbed on the other side by domestic institutions (+1.9 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Accent Microcell Ltd: the Z-score reads 10.47. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 10.47 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 10.47.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Accent Microcell Ltd trades at 36.9× P/E, about the priciest it has ever traded. Its long-run median P/E is 21.7×, measured across 2.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Why this happened. FY26 blended PAT margin was held at 16% by trading dilution — manufacturing segment implicit margin was 20%+. Eliminating or substantially reducing the Rs 90 Cr trading book (which exists purely to retain customer relationships during the approval cycle) would structurally lift blended OPM toward 18-20% as guided. This is not a new catalyst — it is the unwinding of a temporary drag — but it is a meaningful tailwind if Phase 2 executes on schedule.
Today's P/E of 36.9× is about the priciest it has ever traded, against a long-run median of 21.7× measured over 2.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +32.7% against a +176.0% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Accent Microcell Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +31.7% | +21.0% | +21.3% | — |
| Profit | +33.3% | +54.2% | +54.5% | — |
| EPS | +32.7% | +30.3% | +13.3% | — |
| Share price | +176.0% | — | — | — |
4-Factor Sector Score
64.8/100 — rank 4 of 34 in Pharma Formulations · 63% evidence confidence
Accent Microcell Ltd scores 64.8 out of 100 against the 34 companies it is compared with in Pharma Formulations, ranking 4. Price leads the evidence: RS versus the benchmark is 65.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 17.1 + 19.1 + 10.2 + 18.4 = 64.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Accent Microcell Ltd's management promised, set against what actually arrived — 3 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Unit 3 Phase 1 Commercialization Delay · 16 May 2026. Management committed during the May 2025 call to commencing commercial production for Unit 3 Phase 1 by September or October 2025. However, in the May 2026 call, the facility was revealed to still be non-operational, with management providing a new tentative launch date of late June or July 2026, representing an eight to nine-month delay from original projections.
Unit 3 Phase 2 Timeline Revision · 16 May 2026. In the May 2025 call, management projected that Phase 2 of Unit 3 would be commercialized by approximately June 2026. By the May 2026 call, this timeline was significantly delayed to March 2027, a nearly one-year postponement for a project previously characterized as a straightforward brownfield expansion.
Contradictory Disclosures on Environmental Clearances · 16 May 2026. During the May 2025 call, management explicitly denied that any environmental or Pollution Control Board approvals were pending for Unit 3, stating that no such issues existed. Conversely, in the May 2026 call, management admitted that the extensive delays in commercialization were primarily due to unfinished licensing and pending approvals from the Gujarat Pollution Control Board (GPCB).
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 72.1/100Favorable setup82% evidence | LEADER | 30.3/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 18.0/25 ROCE 24.1% · OPM 25% 76% evidence | 6.8/20 P/E 46.7× · PEG — 50% evidence | 17.0/20 RS sector 45% · RS bench 105.2% · 1Y 283.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.3 + 18 + 6.8 + 17 = 72.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 67.1/100Favorable setup100% evidence | BREAKING OUT | 29.9/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.6/25 ROCE 39.8% · OPM 20% 100% evidence | 14.0/20 P/E 21.5× · PEG 1.43 100% evidence | 4.6/20 RS sector -25.4% · RS bench 13.8% · 1Y 14.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.9 + 18.6 + 14 + 4.6 = 67.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -25.4% and the one-year return is 14.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Gland Pharma LtdGLAND | 65.2/100Favorable setup100% evidence | LEADER | 26.6/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.8/25 ROCE 15.1% · OPM 27% 100% evidence | 11.9/20 P/E 42× · PEG 1.45 100% evidence | 12.9/20 RS sector -3.5% · RS bench 44.2% · 1Y 44.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 13.8 + 11.9 + 12.9 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Accent Microcell Ltdthis pageACCENTMIC | 64.8/100Mixed-positive evidence63% evidence | LEADER | 17.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 19.1/25 ROCE 24.9% · OPM 16% 95% evidence | 10.2/20 P/E 36.9× · PEG — 50% evidence | 18.4/20 RS sector 12.6% · RS bench 65.7% · 1Y 151.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 19.1 + 10.2 + 18.4 = 64.8 · Decision use: Price leads the evidence: RS versus the benchmark is 65.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Senores Pharmaceuticals LtdSENORES | 63.7/100Mixed-positive evidence75% evidence | LEADER | 31.7/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 14.8/25 ROCE 15.1% · OPM 30% 76% evidence | 9.6/20 P/E 49.4× · PEG — 15% evidence | 7.6/20 RS sector -6.3% · RS bench 38% · 1Y 90.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.7 + 14.8 + 9.6 + 7.6 = 63.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Corona Remedies LtdCORONA | 63.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 20.6/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.7/25 ROCE 33.3% · OPM 22% 100% evidence | 12.3/20 P/E 61× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 20.6 + 20.7 + 12.3 + 10 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Bliss GVS Pharma LtdBLISSGVS | 63.3/100Mixed-positive evidence82% evidence | LEADER | 28.1/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 15.0/25 ROCE 16.9% · OPM 27% 76% evidence | 6.4/20 P/E 54.4× · PEG — 50% evidence | 13.8/20 RS sector 63.8% · RS bench 128.5% · 1Y 368.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 15 + 6.4 + 13.8 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ipca Laboratories LtdIPCALAB | 61.8/100Mixed-positive evidence82% evidence | LEADER | 24.9/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.9/25 ROCE 17% · OPM 24% 76% evidence | 12.3/20 P/E 36.4× · PEG — 50% evidence | 8.7/20 RS sector -15.4% · RS bench 28% · 1Y 36.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 15.9 + 12.3 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Emcure Pharmaceuticals LtdEMCURE | 59.4/100Mixed-positive evidence75% evidence | LEADER | 25.6/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.1/25 ROCE 24% · OPM 21% 76% evidence | 10.6/20 P/E 35.9× · PEG — 15% evidence | 5.1/20 RS sector -18.5% · RS bench 23.1% · 1Y 45.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 18.1 + 10.6 + 5.1 = 59.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.5% and the one-year return is 45.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Granules India LtdGRANULES | 59.1/100Mixed-positive evidence100% evidence | LEADER | 26.8/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.3/25 ROCE 15.5% · OPM 23% 100% evidence | 10.0/20 P/E 36.4× · PEG 1.27 100% evidence | 7.0/20 RS sector -13.2% · RS bench 29.9% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 15.3 + 10 + 7 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Marksans Pharma LtdMARKSANS | 56.8/100Mixed-positive evidence87% evidence | BREAKING OUT | 24.9/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 16.2/25 ROCE 18.8% · OPM 25% 100% evidence | 6.8/20 P/E 29.6× · PEG 2.85 65% evidence | 8.9/20 RS sector -20.8% · RS bench 59.1% · 1Y 88.1%12 of 12 weeks ahead 70% evidence |
| Exact sum: 24.9 + 16.2 + 6.8 + 8.9 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Rubicon Research LtdRUBICON | 56.8/100Mixed-positive evidence73% evidence | BREAKING OUT | 22.6/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 28.4% · OPM 24% 100% evidence | 6.0/20 P/E 96.3× · PEG 2.41 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 170.9%12 of 12 weeks ahead 0% evidence |
| Exact sum: 22.6 + 18.2 + 6 + 10 = 56.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13Ind-Swift Laboratories LtdINDSWFTLAB | 54.5/100Mixed-positive evidence87% evidence | LEADER | 22.1/35 Revenue 53.9% · PAT -74.3% · OPM change 14.6 pp 95% evidence | 4.9/25 ROCE 4.9% · OPM 17% 95% evidence | 7.5/20 P/E 54× · PEG — 50% evidence | 20.0/20 RS sector 73.1% · RS bench 145.3% · 1Y 288.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 4.9 + 7.5 + 20 = 54.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Caplin Point Laboratories LtdCAPLIPOINT | 54.3/100Mixed-positive evidence100% evidence | LEADER | 16.2/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 18.0/25 ROCE 24.2% · OPM 35% 100% evidence | 11.0/20 P/E 32.4× · PEG 1.52 100% evidence | 9.1/20 RS sector -6.9% · RS bench 39.9% · 1Y 21%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 18 + 11 + 9.1 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Ajanta Pharma LtdAJANTPHARM | 51.8/100Mixed-positive evidence100% evidence | LEADER | 19.4/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 20.1/25 ROCE 34.5% · OPM 26% 100% evidence | 6.9/20 P/E 39.1× · PEG 2.31 100% evidence | 5.4/20 RS sector -19.2% · RS bench 22.3% · 1Y 39.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 20.1 + 6.9 + 5.4 = 51.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Fredun Pharmaceuticals Ltd539730 | 51.6/100Thin evidence · provisional50% evidence | 16.8/35 Revenue — · PAT — · OPM change 0 pp 24% evidence | 14.8/25 ROCE 21.3% · OPM 14% 76% evidence | 9.1/20 P/E 58.4× · PEG — 15% evidence | 10.9/20 RS sector -29% · RS bench 133.6% · 1Y 26%0 of 6 weeks ahead to 2026-08-16 100% evidence | |
| Exact sum: 16.8 + 14.8 + 9.1 + 10.9 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17RPG Life Sciences LtdRPGLIFE | 51.1/100Mixed-positive evidence93% evidence | LEADER | 9.4/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.6/25 ROCE 25.7% · OPM 22% 100% evidence | 11.5/20 P/E 43.2× · PEG 1.43 65% evidence | 12.6/20 RS sector -11.3% · RS bench 34.8% · 1Y 25%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 17.6 + 11.5 + 12.6 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Strides Pharma Science LtdSTAR | 49.9/100Mixed-negative evidence75% evidence | TURNING | 19.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.2/25 ROCE 18.3% · OPM 18% 76% evidence | 11.5/20 P/E 18.8× · PEG — 15% evidence | 6.0/20 RS sector -18.6% · RS bench 23.7% · 1Y 36%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 13.2 + 11.5 + 6 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Akums Drugs & Pharmaceuticals LtdAKUMS | 49.4/100Mixed-negative evidence75% evidence | LEADER | 11.9/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.7/25 ROCE 14.9% · OPM 15% 76% evidence | 10.0/20 P/E 42.3× · PEG — 15% evidence | 16.8/20 RS sector 3.7% · RS bench 54.1% · 1Y 72%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 10.7 + 10 + 16.8 = 49.4 · Decision use: Price leads the evidence: RS versus the benchmark is 54.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Wockhardt LtdWOCKPHARMA | 49.4/100Mixed-negative evidence74% evidence | TURNING | 24.0/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.4/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 92.3× · PEG — 15% evidence | 11.2/20 RS sector -2% · RS bench 46.5% · 1Y 50.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 5.4 + 8.8 + 11.2 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Zydus Lifesciences LtdZYDUSLIFE | 48.9/100Mixed-negative evidence100% evidence | LEADER | 10.5/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.9/25 ROCE 21.1% · OPM 24% 100% evidence | 15.6/20 P/E 24.7× · PEG 1.23 100% evidence | 5.9/20 RS sector -18.8% · RS bench 23.4% · 1Y 16.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 16.9 + 15.6 + 5.9 = 48.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22Suven Life Sciences LtdSUVEN | 47.8/100Mixed-negative evidence67% evidence | LEADER | 19.6/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.3/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.9/20 RS sector 4.2% · RS bench 52% · 1Y 49.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 2.3 + 10 + 15.9 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Kilitch Drugs (India) LtdKILITCH | 47.0/100Mixed-negative evidence87% evidence | TURNING | 11.5/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.4/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.4/20 P/E 26.1× · PEG — 50% evidence | 11.7/20 RS sector -13.3% · RS bench 33.1% · 1Y 24.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 9.4 + 14.4 + 11.7 = 47 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 46.9/100Mixed-negative evidence87% evidence | LEADER | 12.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 16.8/25 ROCE 22.7% · OPM 21% 95% evidence | 11.7/20 P/E 34× · PEG — 50% evidence | 5.7/20 RS sector -21.3% · RS bench 20% · 1Y -0.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 16.8 + 11.7 + 5.7 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 44.3/100Mixed-negative evidence96% evidence | 9.3/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.9/25 ROCE 25.4% · OPM 22% 100% evidence | 4.3/20 P/E 53.8× · PEG 2.34 100% evidence | 9.8/20 RS sector -8.2% · RS bench 23.5% · 1Y 40.5%2 of 2 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 9.3 + 20.9 + 4.3 + 9.8 = 44.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Gufic BioSciences LtdGUFICBIO | 41.6/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.7/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 10.1/25 ROCE 12.3% · OPM 18% 100% evidence | 3.5/20 P/E 57.9× · PEG 4.78 100% evidence | 7.3/20 RS sector -21.1% · RS bench 26.1% · 1Y 14.5%12 of 12 weeks ahead 70% evidence |
| Exact sum: 20.7 + 10.1 + 3.5 + 7.3 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Alembic Pharmaceuticals LtdAPLLTD | 41.4/100Mixed-negative evidence94% evidence | BREAKING OUT | 14.1/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.8/25 ROCE 12.6% · OPM 15% 100% evidence | 13.2/20 P/E 22.8× · PEG 1.74 100% evidence | 5.3/20 RS sector -26.6% · RS bench 9.7% · 1Y -9.9%6 of 12 weeks ahead 70% evidence |
| Exact sum: 14.1 + 8.8 + 13.2 + 5.3 = 41.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 28Aurobindo Pharma LtdAUROPHARMA | 39.8/100Mixed-negative evidence100% evidence | LEADER | 14.6/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.7/25 ROCE 12.9% · OPM 21% 100% evidence | 6.0/20 P/E 26× · PEG 2.67 100% evidence | 6.5/20 RS sector -14.7% · RS bench 28.4% · 1Y 53%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 12.7 + 6 + 6.5 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Bafna Pharmaceuticals LtdBAFNAPH | 39.2/100Mixed-negative evidence60% evidence | BREAKING OUT | 11.1/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.6/20 P/E 106× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 107.9% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 11.1 + 7.3 + 8.6 + 12.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.9/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.0/20 RS sector -34.4% · RS bench 12.5% · 1Y -15.7%8 of 11 weeks ahead 70% evidence |
| Exact sum: 18.9 + 4.3 + 10 + 5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Bharat Parenterals LtdBPLPHARMA | 35.7/100Thin evidence · provisional58% evidence | 11.6/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.0/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.1/20 RS sector -13.5% · RS bench 54.8% · 1Y 44.1%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 11.6 + 4 + 10 + 10.1 = 35.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Torrent Pharmaceuticals LtdTORNTPHARM | 35.5/100Mixed-negative evidence100% evidence | LEADER | 15.3/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 15.2% · OPM 34% 100% evidence | 1.0/20 P/E 85× · PEG 5.11 100% evidence | 4.3/20 RS sector -21.1% · RS bench 19.6% · 1Y 37.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 14.9 + 1 + 4.3 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 33Zim Laboratories LtdZIMLAB | 34.5/100Adverse evidence79% evidence | LEADER | 8.7/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.2/25 ROCE 4.8% · OPM 2.6% 95% evidence | 6.3/20 P/E 201× · PEG — 50% evidence | 13.3/20 RS sector 6% · RS bench 56.4% · 1Y 83%11 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 6.2 + 6.3 + 13.3 = 34.5 · Decision use: Price leads the evidence: RS versus the benchmark is 56.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Jubilant Pharmova LtdJUBLPHARMA | 33.7/100Adverse evidence93% evidence | TURNING | 8.7/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 5.8/25 ROCE 9% · OPM 11% 100% evidence | 13.4/20 P/E 44× · PEG 1.17 65% evidence | 5.8/20 RS sector -27.9% · RS bench 11.8% · 1Y -2.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 5.8 + 13.4 + 5.8 = 33.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Accent Microcell Ltd's share price today?
Accent Microcell Ltd trades at ₹675, +176.0% over the past year. The company is valued at ₹1,619 Cr. The stock sits at 88% of its 52-week range of ₹308–₹726, +44.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 63 weeks in. — as of 25 September 2026.
What were Accent Microcell Ltd's latest quarterly results?
Accent Microcell Ltd reported revenue of ₹210 Cr and net profit of ₹26.0 Cr for the Mar 26 quarter. Revenue rose 51.1% and profit rose 52.9% year on year. Earnings per share were ₹10.75. The operating margin was 16.0%, 1.0 pp lower than a year earlier. — as of 25 September 2026.
What is Accent Microcell Ltd's revenue?
Accent Microcell Ltd reported revenue of ₹210 Cr in the Mar 26 quarter, +51.1% year on year. For the full FY26 fiscal year, revenue was ₹349 Cr (+31.7%). Over the last 7 years revenue compounded at 17.3% a year. — as of 25 September 2026.
What is Accent Microcell Ltd's profit?
Accent Microcell Ltd earned ₹26.0 Cr of net profit in the Mar 26 quarter, +52.9% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹44.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 25 September 2026.
What is Accent Microcell Ltd's market cap?
Accent Microcell Ltd's market capitalisation is ₹1,619 Cr at a share price of ₹675. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
What is Accent Microcell Ltd's P/E ratio?
Accent Microcell Ltd trades at a P/E of 36.9×, at the 98th percentile of its own 3-year range, against a long-run median of 21.7×. This is a comparison with the stock's own history, not a value call — as of 25 September 2026.
Does Accent Microcell Ltd pay a dividend?
Yes — Accent Microcell Ltd's dividend payout was 5% of profit in FY26, and it recorded a payout in 6 of its last 8 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is Accent Microcell Ltd overvalued?
On its own history, Accent Microcell Ltd looks expensive: its P/E of 36.9× sits at the 98th percentile of its 3-year range (long-run median 21.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 25 September 2026.
Is Accent Microcell Ltd growing?
Yes — Accent Microcell Ltd is growing: latest-quarter revenue +51.1% year on year, profit +52.9%, and the margin −1.0 pp at 16.0%. The 7-year compound rates are 17.3% (revenue) and 40.9% (profit). The earnings engine currently reads: improving — as of 25 September 2026.
How is Accent Microcell Ltd performing?
Accent Microcell Ltd is in a confirmed uptrend, 63 weeks in. Its latest quarter's revenue rose 51.1% and profit rose 52.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 50 weeks. This describes what the data did, not a rating. — as of 25 September 2026.
Is Accent Microcell Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 63 of stage 2), trading +44.1% versus its 200-day average and at 88% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Is Accent Microcell Ltd beating the market?
On recent form, yes — Accent Microcell Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 50 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.8 years the stock moved +126% against the NIFTY 500's +20% — ahead of the index over the full window. — as of 25 September 2026.
Will Accent Microcell Ltd's share price go up?
This page publishes no price forecast for Accent Microcell Ltd. What it measures instead: the share price is ₹675, the price is in a confirmed uptrend 63 weeks in. Its P/E of 36.9× sits at the 98th percentile of its own 3-year range. — as of 25 September 2026.
Who owns Accent Microcell Ltd?
Promoters hold 53.0% of Accent Microcell Ltd, foreign institutions 0.9%, domestic institutions 3.5% and the public 42.5% (latest quarter). The biggest move on the register over the last two years: Promoters cut 2.1 points over 7 quarters. — as of 25 September 2026.
Does Accent Microcell Ltd have too much debt?
No — Accent Microcell Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 57×. FY26 borrowings were ₹1.0 Cr against equity of ₹276 Cr. The returns on this page are earned, not borrowed — as of 25 September 2026.
What is Accent Microcell Ltd's capex?
Accent Microcell Ltd spent ₹137 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹99.0 Cr, with ₹102 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 25 September 2026.
What is Accent Microcell Ltd's cash flow?
Accent Microcell Ltd generated ₹19.0 Cr of operating cash flow in FY26 and ₹−80.0 Cr of free cash flow after ₹99.0 Cr of capital spending. Reported profit that year was ₹44.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 25 September 2026.
Is Accent Microcell Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 51% of Accent Microcell Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹19.0 Cr against reported profit of ₹44.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 25 September 2026.
How financially safe is Accent Microcell Ltd?
On the balance sheet, the Z-score reads 10.47 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 25 September 2026.
Where is Accent Microcell Ltd in its business cycle?
Accent Microcell Ltd's FY26 operating margin was 16.0%, against a 8-year band of 4.9%–16.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What could break the Accent Microcell Ltd story?
The sharpest disagreement: profits are rising, but only 51% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is Accent Microcell Ltd a stock worth studying right now?
This is not investment advice. The machine read: Accent Microcell Ltd's price has outrun its earnings. +176.0% in a year against EPS +32.7% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!